HF
EIDX

HRT Financial’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

HRT Financial’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-16,047
Closed -$577K – 1853
2019
Q3 		$577K Buy
+16,047
New +$627K 0.03% 603

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

HRT Financial's EIDX Position: Q4 2019 in Review

HRT Financial sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q4 2019, closing a stake of 16,047 shares — an estimated $577K sold.

HRT Financial first reported a position in EIDX in Q3 2019 and held it in 1 quarter. The position peaked at $577K in Q3 2019. 102 funds tracked by Wall St. Rank hold EIDX as of Q4 2019.

  • HRT Financial reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • HRT Financial sold 16,047 Eidos Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $577K.
  • HRT Financial first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • HRT Financial's Eidos Therapeutics, Inc. Common Stock position peaked at $577K in Q3 2019.
  • 102 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q4 2019.

Based on HRT Financial's 13F filing for Q4 2019, filed 14 Feb 2020.